Biologicals

Molecular Methods

Vaccines and other biological medicines are derived from living materials. This poses particular problems with regard to assuring their efficacy and safety due to the inherent variability of starting materials, the production processes, and the complex nature of the products themselves. For vaccines and other biological medicines, the key to effective quality control (QC) is rigorous testing and validation applied to the starting materials, to different stages of the production process, and also to the final products.

With the advent of molecular biotechnology, there are increasing uses of molecular methods for the characterization and QC of vaccines whether they are currently used or newly developed. The World Health Organization Expert Committee on Biological Standardization (WHO ECBS) has put an increasing emphasis on products and assays arising from new biotechnology in internationally harmonized activities of quality assurance and safety of biologicals, and of vaccines in particular.


RELATED LINKS

UPCOMING EVENTS

WHO Implementation Workshop: Characterization of cell banks for the production of biologicals, 27-29 May 2013 and WHO Informal Consultation on regulatory risk assessment in the case of adventitious agent finding in a marketed vaccine, 30-31 May 2013, Beijing, Republic of China

WHO Informal Consultation on the Scientific and Regulatory Considerations on the Stability Evaluation of Vaccines under a Controlled Temperature Chain, Langen, Germany, 4-6 June 2013

Expert Committee on Biological Standardization, Geneva, Switzerland, 21-25 October 2013

CONTACTS

Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971